Tigermed, Fosun, Haisco and Sinopharm-CICC all scored exits as the oncology and metabolic disorder therapeutics went public in China.

China-based cancer and metabolic disorder drug developer Hinova Pharmaceuticals floated on Tuesday in an initial public offering sized at approximately RMB1.06bn ($166m), enabling corporates Tigermed, Fosun, Haisco and Sinopharm to exit, DealStreetAsia reported.

The company issued nearly 24.8 million shares on Shanghai Stock Exchange’s Star Market, priced at RMB42.90 each, with Citic Securities lead underwriter for the offering.

Hinova is working on therapeutics intended to treat cancer and metabolic diseases through targeted protein degradation. It initiated a phase 1 clinical…

Subscribe to go deeper

GCV subscribers get access to all our proprietary data and deep-dive articles, as well as the global directory of CVC investors.



Not sure if you have a subscription?
Robert Lavine

Robert Lavine is special features editor for Global Venturing.
Email LinkedIn